CClinicalTrials.gg
Sign In
RecruitingNCT07606573Updated Jun 11, 2026

The SEAS Study: Sensory Engagement and Activation During Noninvasive Stimulation

An interventional study of External electrical stimulation and Ultrasound stimulation in Healthy Adult Participants, sponsored by University of Minnesota. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by University of Minnesota · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Jun 2026; still recruiting 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Early feasibility study to establish quantitative physiological markers correlated with noninvasive stimulation.

Read the detailed description

This pilot early feasibility study in healthy participants is intended to establish quantitative physiological markers of cortical and autonomic modulation evoked by noninvasive electrical and/or ultrasound stimulation of the nervous system.

02

Conditions studied

  • Healthy Adult Participants
03

In context

Lead sponsor

University of Minnesota is the lead sponsor of 1,184 studies on the registry; 195 are open to participants now.

Of its 132 completed or terminated interventional studies of FDA-regulated products, 91 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Able to provide written informed consent in English.
  • Willing and able to complete study procedures (e.g., \~1-hour sessions with non-invasive recordings, \~3-hour visit).

Exclusion criteria

Exclusion Criteria:

  • History of neurological disorders (e.g., epilepsy, migraines) or psychiatric conditions requiring medication.
  • Active implanted medical devices (e.g., pacemakers, cochlear implants) or metal in the neck/forearm that could interfere with stimulation or recordings.
  • Skin conditions or open wounds at stimulation sites (cervical neck, forearm).
  • Women who are pregnant or breastfeeding.
  • Current use of medications affecting autonomic or cortical function (e.g., beta-blockers, sedatives).
  • Inability to sit still for recordings or understand instructions (e.g., due to severe vision/hearing impairment).
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Acute electrical stimulation session versus no stimulation (sham).

    Device: External electrical stimulation

  • Experimental
    Acute ultrasound stimulation session versus no stimulation (sham).

    Device: Ultrasound stimulation

Interventions

  • DeviceExternal electrical stimulation

    Electrical stimulation

  • DeviceUltrasound stimulation

    USS

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HD-EEG Power Spectrum Magnitude After Active Versus Sham Stimulation

    Change from baseline in power spectrum magnitude will be calculated from high-density electroencephalography recordings in standard EEG frequency bands. The primary comparison will be the within-participant difference in change from baseline between active stimulation and sham stimulation conditions.

    Time frame: Baseline and post-stimulation assessment during the study visit, approximately 3 hours.

07

Study locations

3 of 3 sites recruiting
  • M Health Clinical Research Unit
    Minneapolis, Minnesota 55455, United States
    Recruiting
  • M Health Clinics and Surgery Center and satellite Neurology Clinic locations
    Minneapolis, Minnesota 55455, United States
    Recruiting
  • Translational Neurotechnology (TNT) Lab
    Minneapolis, Minnesota 55455, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07606573
Lead sponsor
University of Minnesota
Responsible party
Sponsor
First posted
May 26, 2026
Start date
Jun 8, 2026
Primary completion
Jul 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jun 11, 2026

Study contacts

Rosana Esteller, Principal Investigator, PhD
Contact
tntlab-studies@umn.edu
612-624-1326
Sanjay Balaji, Study Coordinator, Ph.D.
Contact
tntlab-studies@umn.edu

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University of Minnesota

Start the discussion